Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial.

Piccirillo MC, Bonanno L, Garassino MC, Esposito G, Dazzi C, Cavanna L, Burgio MA, Rosetti F, Rizzato S, Morgillo F, Cinieri S, Veccia A, Papi M, Tonini G, Gebbia V, Ricciardi S, Pozzessere D, Ferro A, Proto C, Costanzo R, D'Arcangelo M, Proietto M, Gargiulo P, Di Liello R, Arenare L, De Marinis F, Crinò L, Ciardiello F, Normanno N, Gallo C, Perrone F, Gridelli C, Morabito A

Open source

DOI: 10.1016/j.jtho.2022.05.008
Published: 2022 Sep
Container: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jtho.2022.05.008,
  title = {Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial.},
  author = {Piccirillo MC and Bonanno L and Garassino MC and Esposito G and Dazzi C and Cavanna L and Burgio MA and Rosetti F and Rizzato S and Morgillo F and Cinieri S and Veccia A and Papi M and Tonini G and Gebbia V and Ricciardi S and Pozzessere D and Ferro A and Proto C and Costanzo R and D'Arcangelo M and Proietto M and Gargiulo P and Di Liello R and Arenare L and De Marinis F and Crinò L and Ciardiello F and Normanno N and Gallo C and Perrone F and Gridelli C and Morabito A},
  year = {2022},
  journal = {Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  doi = {10.1016/j.jtho.2022.05.008},
  url = {https://doi.org/10.1016/j.jtho.2022.05.008}
}

RIS

TY  - JOUR
TI  - Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial.
AU  - Piccirillo MC
AU  - Bonanno L
AU  - Garassino MC
AU  - Esposito G
AU  - Dazzi C
AU  - Cavanna L
AU  - Burgio MA
AU  - Rosetti F
AU  - Rizzato S
AU  - Morgillo F
AU  - Cinieri S
AU  - Veccia A
AU  - Papi M
AU  - Tonini G
AU  - Gebbia V
AU  - Ricciardi S
AU  - Pozzessere D
AU  - Ferro A
AU  - Proto C
AU  - Costanzo R
AU  - D'Arcangelo M
AU  - Proietto M
AU  - Gargiulo P
AU  - Di Liello R
AU  - Arenare L
AU  - De Marinis F
AU  - Crinò L
AU  - Ciardiello F
AU  - Normanno N
AU  - Gallo C
AU  - Perrone F
AU  - Gridelli C
AU  - Morabito A
PY  - 2022
JO  - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
DO  - 10.1016/j.jtho.2022.05.008
UR  - https://doi.org/10.1016/j.jtho.2022.05.008
ER  -

APA

MC, P., L, B., MC, G., G, E., C, D., L, C., MA, B., F, R., S, R., F, M., S, C., A, V., M, P., G, T., V, G., S, R., D, P., A, F., C, P., R, C., M, D., M, P., P, G., R, D. L., L, A., F, D. M., L, C., F, C., N, N., C, G., F, P., C, G., & A, M. (2022). Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. https://doi.org/10.1016/j.jtho.2022.05.008

Source records

pubmed · retrieved 2026-09-27T00:36:14.682Z
europe-pmc · retrieved 2026-09-27T00:36:14.772Z